Proposal for a Scientifically Correct and Medically Actionable Disease Classification System (ICD) for Obesity
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Objective: Obesity is responsible for a huge burden of suffering and social costs, and yet many patients lack access to evidence‐based therapies. The diagnostic term “obesity” and inadequate International Classification of Diseases(ICD) codes contribute to suboptimal efforts to prevent and treat obesity as a chronic disease. The goal of this review is to develop a medically actionable classification system based on the diagnostic term “adiposity‐based chronic disease” (ABCD) that reflects disease pathophysiology and specific complications causing morbidity and mortality. Methods: A coding system based on the diagnosis of ABCD with four domains is proposed: A codes reflect pathophysiology, B codes indicate BMI classification, C codes specify specific biomechanical and cardiovascular complications remediable by weight loss, and D codes indicate the degree of the severity of complications. Supplemental codes identify aggravating factors that complicate care and that are relevant to a personalized therapeutic plan. Results: The coding system addresses pathophysiology and therapeutic goals and differential risk, presence, and severity of specific complications that are integral to ABCD as a chronic disease. Conclusions: The scientifically correct and medically actionable approach to diagnosis and disease coding will lead to greater acknowledgement of ABCD as a disease and accessibility to evidence‐based therapies on behalf of patients across the life cycle.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
Macrophages, inflammation, and insulin resistance
Olefsky, J. M., & Glass, C. K. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135846 · Cited by 2,733
Kanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914 · cited 6×
“Note that weight loss associated with bariatric surgery has been shown to reduce CVD events and decrease mortality (7).”
BackgroundSelf-citationIncreasing Prevalence of the Metabolic Syndrome Among U.S. Adults
Ford, E. S., Giles, W. H., & Mokdad, A. H. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2444 · Cited by 1,488
Long-term persistence of hormonal adaptations to weight loss
Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105816 · Cited by 1,449 · cited 2×
“The insulin-resistant state is central to the pathophysiology of cardiometabolic disease via the following: (1) defects in glucose homeostasis, substrate oxidation, and mitochondrial function; (2) increased inflammation and oxidative stress; (3) alterations in lipids and lipoproteins contributing to CVD risk; (4) impa…”
BackgroundObesity as a Disease: The Obesity Society 2018 Position Statement
Jastreboff, A. M., Kotz, C. M., Kahan, S., Kelly, A. S., & Heymsfield, S. B. (2019) · Obesity · doi:10.1002/oby.22378 · Cited by 457 · cited 4×
“The insulin-resistant state is central to the pathophysiology of cardiometabolic disease via the following: (1) defects in glucose homeostasis, substrate oxidation, and mitochondrial function; (2) increased inflammation and oxidative stress; (3) alterations in lipids and lipoproteins contributing to CVD risk; (4) impa…”
BackgroundInfluentialSabin, J. A., Marini, M., & Nosek, B. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048448 · Cited by 439
Roles of diacylglycerols and ceramides in hepatic insulin resistance
Petersen, M. C., & Shulman, G. I. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.04.004 · Cited by 373
Mechanick, J. I., Hurley, D. L., & Garvey, W. T. (2017) · Endocrine Practice · doi:10.4158/ep161688.ps · Cited by 320 · cited 3×
“The AACE has proposed a new diagnostic term, “adiposity-based chronic disease” (ABCD) (8), which has also been recently embraced by the European Association for the Study of Obesity (EASO) (36).”
BackgroundMethodSelf-citation
Cited by
Obesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Hassapidou, M., Vlassopoulos, A., Kalliostra, M., Govers, E., Mulrooney, H., Ells, L., Salas, X. R., Muscogiuri, G., Darleska, T. H., Busetto, L., et al. (2023) · Obesity Facts · doi:10.1159/000528083 · Cited by 121
New horizons. A new paradigm for treating to target with second-generation obesity medications
Garvey, W. T. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab848 · Cited by 110
Self-citationNadolsky, K., Addison, B., Agarwal, M., Almandoz, J. P., Bird, M. D., DeGeeter Chaplin, M., Garvey, W. T., & Kyle, T. K. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.03.272 · Cited by 86
Self-citationWeight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes
Finer, N. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14569 · Cited by 45
Kessler, C. (2021) · Nursing Clinics of North America · doi:10.1016/j.cnur.2021.08.001 · Cited by 43
Metadata
- Authors
- Garvey, W. T., & Mechanick, J. I.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2020-02-24
- Volume
- 28
- Issue
- 3
- Pages
- 484-492
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W3007430263
- Cited by
- 101
- References
- 19
- FWCI
- 24.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.